Merck & Co., Inc. filings document the regulatory record of a New Jersey pharmaceutical issuer with common stock and multiple debt securities registered on the New York Stock Exchange. The company's disclosures cover operating and financial results, clinical and regulatory matters, material agreements, governance matters and capital-structure changes.
Merck's SEC record includes Form 8-K material-event reports, definitive proxy materials and debt-financing disclosures. Recent filings describe underwritten public offerings of notes, registered securities, shareholder voting matters, board and executive-governance information, and other events tied to the company's pharmaceutical, vaccine and animal health businesses.
Merck & Co., Inc.’s EVP and CFO Caroline Litchfield reported receiving 15,852 shares of common stock on January 26, 2026. The shares were distributed after performance criteria were met for performance share units granted on March 31, 2023.
The performance shares were paid out at 94 percent of target awards and include dividends that accrued over the three-year performance period ending December 31, 2025. Following this award, Litchfield beneficially owns 90,192.194 shares of Merck common stock directly.
Merck & Co., Inc. Executive VP & President, MRL Dean Y. Li reported an acquisition of 20,469 shares of Merck common stock on January 26, 2026. The shares were distributed after performance criteria were met for performance share units granted on March 31, 2023, with performance paid out at 94 percent of the target award and including dividends accrued over a three-year period ending December 31, 2025.
Following this distribution, Li beneficially owned 102,270.05 Merck shares in direct form, which also include shares acquired through dividend reinvestment transactions.
Merck & Co., Inc. Chief Marketing Officer Chirfi Guindo reported receiving 9,865 shares of common stock on January 26, 2026, coded as an acquisition. The shares were valued at $107.4 per share and resulted from performance share units granted on March 31, 2023.
The award reflects performance shares paid out at 94 percent of target, including dividends accrued over a three-year performance period ending December 31, 2025. After this transaction, Guindo beneficially owns 100,615.127 Merck common shares directly, plus 56.7708 shares held indirectly through a 401(k) plan.
Merck & Co., Inc. executive Richard R. DeLuca, Jr., EVP & President of Merck Animal Health, reported receiving 12,264 shares of Merck common stock on January 26, 2026. These shares were distributed after performance criteria were met for performance share units granted on March 31, 2023.
Performance shares were paid at 94 percent of target awards and include dividends accrued over the three-year performance period ending December 31, 2025. After this award, DeLuca beneficially owned 197,858.834 shares of common stock directly and 1,312.5134 shares indirectly through the Merck U.S. Savings Plan, a 401(k) plan.
Merck & Co., Inc. Chairman, CEO & President Robert M. Davis reported an acquisition of common stock tied to a performance award. On January 26, 2026, he received 47,434 shares of common stock at a stated price of $107.4 per share, coded as an acquisition. The footnote explains this was a distribution of net after‑tax shares following satisfaction of performance criteria for performance share units granted on March 31, 2023, with performance shares paid out at 94% of target awards, including accrued dividends over a three‑year performance period ending December 31, 2025. After this distribution, Davis directly beneficially owns 491,035.757 common shares.
Merck & Co., Inc. executive Sanat Chattopadhyay acquired 13,880 shares of common stock on January 26, 2026. The shares were distributed after performance criteria were met for performance share units granted on March 31, 2023, which paid out at 94 percent of target and included dividends accrued over a three-year period ending December 31, 2025.
Following this transaction, he directly holds 13,880 Merck shares and indirectly holds additional shares through three Grantor Retained Annuity Trusts with 74,289, 57,622, and 53,417 shares respectively, over which he maintains complete investment control as sole trustee.
Merck & Co., Inc. director Christine E. Seidman reported routine changes in her equity holdings. On 12/31/2025 she disposed of 100 shares of Merck common stock. The filing also shows an acquisition of 77.1898 phantom stock units tied to Merck common stock at a reference price of $105.26 per share, bringing her total phantom stock holdings to 19,025.6686 units held directly.
According to the disclosure, each phantom stock unit is on a 1-for-1 basis with Merck common stock and will be settled 100% in cash after her termination of service, under the company’s deferred compensation plan for directors. Her holdings also include shares previously acquired through dividend reinvestment.
Merck & Co., Inc. director Thomas H. Glocer reported an equity compensation update. On 12/31/2025, he acquired 463.1389 phantom stock units, which are linked on a 1-for-1 basis to Merck common stock and are to be settled entirely in cash after his termination of service, under the company’s Plan for Deferred Payment of Directors' Compensation.
Following this transaction, he beneficially owns 107,075.6744 phantom stock units and 5,100 shares of Merck common stock directly. The holdings include shares accumulated through dividend reinvestment. Phantom stock gives economic exposure to the share price without issuing actual shares.
Merck & Co., Inc. director Mary Ellen Coe reported an acquisition of derivative securities linked to the company’s common stock. On 12/31/2025, she received 285.0086 phantom stock units, each tied on a 1-for-1 basis to Merck common shares, at a reference price of $105.26 per unit. Following this transaction, she holds 29,231.5716 phantom stock units directly.
The phantom stock units are to be settled 100% in cash upon her termination of service, according to a distribution schedule elected under Merck’s Plan for Deferred Payment of Directors’ Compensation. Her holdings also include shares acquired through dividend reinvestment, reflecting ongoing participation in Merck’s director compensation and deferral programs rather than open-market share purchases.
Merck & Co., Inc. reported that on December 4, 2025 it closed an underwritten public offering of multiple series of senior notes under its automatic shelf registration. The offering includes $500,000,000 aggregate principal amount of Floating Rate Notes due 2029, $750,000,000 of 3.850% Notes due 2029, $1,000,000,000 of 4.150% Notes due 2031 and $1,000,000,000 of 4.450% Notes due 2032.
Merck also issued $1,500,000,000 of 4.750% Notes due 2035, $750,000,000 of 5.500% Notes due 2046, $1,500,000,000 of 5.550% Notes due 2055 and $1,000,000,000 of 5.700% Notes due 2065. The notes were issued under an existing indenture dated January 6, 2010 with U.S. Bank Trust National Association as trustee, and related officers’ certificates and a legal opinion were filed as exhibits.